

Arrigo Recordati International Prize for Scientific Research awarded to Filippo Crea

The Prize was awarded to the scientist for his contribution in researching the pivotal role of microcirculation in systemic and organ diseases.

The theme of the 2015 Edition of the Arrigo Recordati Prize will be: “*Secondary prevention and risk reduction strategies for patients with cardiovascular diseases*”.

Milan, June 15, 2013

Today the seventh edition of the Arrigo Recordati International Prize for Scientific Research came to its conclusion with 100,000 Euros being awarded to Prof. **Filippo Crea**, Full Professor in Cardiology at Policlinico “Agostino Gemelli”, Rome, Italy. The ceremony took place during the 23rd ESH (European Society of Hypertension) Annual Meeting in Milan.

The Arrigo Recordati International Prize for Scientific Research was established in 2000, in memory of the Italian pharmaceutical entrepreneur Arrigo Recordati, who led the homonymous company through a period of intense growth and development for 48 years until his premature death in February 1999. The Prize recognizes the seminal work of an individual who has demonstrated, through dedication to research, the values recognized by Arrigo Recordati, by granting every two years a prize of 100,000 Euros to a distinguished scientist, of any nationality, working in an institutional setting and not affiliated with pharmaceutical or medical device companies, for his/her commitment and accomplishments in the field of cardiovascular disease. Each edition of the Prize is devoted to a specific theme in this field.

For the 2013 edition of the Prize, relevant international societies and organizations were invited to nominate candidates that they felt merited the award for lifetime achievement in researching the pivotal role of microcirculation in systemic and organ diseases. Self-nominations were not considered.

The Jury panel of the 2013 edition of the Prize, who announced the final decision, is composed of experts who have provided leadership throughout their long careers in the field of cardiology and microcirculation. The jury is chaired by **Mara Lorenzi**, MD, Professor of Ophthalmology, Harvard Medical School, Senior Scientist and George and Frances Levin Scholar in Diabetic Retinopathy, Schepens Eye Research Institute Massachusetts Eye and Ear, Boston, MA, USA. Members of the Jury are **Ignatios Ikonomidis**, MD, Ph.D., FESC, Assistant Professor in Cardiology, Director of the Laboratory of Preventive Cardiology, 2nd Cardiology Department, National and Kapodistrian University of Athens Attikon University Hospital, Athens, Greece and **Can Ince**, Ph.D., Professor of Clinical Physiology, Dept. of Translational Physiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, Dept. of Intensive Care Adults, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Professor Lorenzi, on behalf of the Jury, officially awarded the winner with the following motivation: “*The Recordati Prize recognizes Professor Filippo Crea for his outstanding contributions in researching the pivotal role of microcirculation in systemic and organ diseases*”.

The winner of the Arrigo Recordati Prize, after expressing his satisfaction for the important award, gave a brief lecture summarizing his research efforts and results in the study of the pivotal role of microcirculation in systemic and organ diseases.

Throughout his professional career, Professor Filippo Crea has kept a consistent focus on clinical conditions related to dysfunction of the coronary microcirculation, identifying the clinical impact of events occurring in the coronary microcirculation, uncovering mechanisms, and pioneering therapeutic approaches.

Finally, Giovanni Recordati, Arrigo Recordati’s son and current Chairman and CEO of the Recordati pharmaceutical company, renewed the Company’s strong commitment to research and officially announced that the theme chosen for the eighth edition of the Arrigo Recordati Prize is: “*Secondary prevention and risk reduction strategies for patients with cardiovascular diseases*”.

Every year, millions of people are admitted to hospitals and intensive care units following acute cardiovascular events. Most of these patients receive “*state of the art*” medical and interventional care during their hospitalization.

However, observational data suggest that, after discharge from the hospital, patients are neither properly followed nor receive appropriate evidence-based treatments, even though a large body of evidence supporting the value and effectiveness of secondary prevention of acute cardiovascular events is currently available.

Thus, it seems clear that secondary prevention is not fully implemented in many cases of acute cardiovascular events. Secondary prevention should aim to reduce the risk of these events, thus reducing the need for interventional procedures, improving quality of life and in the end, extend survival of the affected patients.

Important new evidence has emerged that further supports and broadens the merits of intensive and comprehensive risk-reduction therapies for patients with cardiovascular diseases, including atherosclerotic vascular disease and peripheral artery diseases. Evidence-based recommendations and guidelines for secondary cardiovascular prevention are available, and are the key reference for clinical intervention. Therapeutic lifestyle changes including identification and treatment of established risk factors (especially hypertension, smoking, dyslipidemia, diabetes, obesity or poor diet, and physical inactivity) are of proven benefit and are regarded as major strategies to improve outcomes and diminish premature morbidity and mortality from cardiovascular diseases (CVD). Adjunctive drug therapies (such as aspirin, statins, anti-hypertensive drugs) have proven benefits.

The great impact of innovative scientific and clinical research accomplished in the field of secondary prevention and risk reduction strategies for patients with cardiovascular diseases must be recognized and acknowledged.

The Arrigo Recordati Prize in its next edition of 2015 will seek to identify a leading contributor in this highly relevant area of medical research.

About Recordati

Recordati, founded in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange, with a total staff of over 3,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey and in the United States of America. A field force of more than 1,700 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases.

For more information on the International Prize Arrigo Recordati, please contact the Organizing Secretariat: AIM Group International – AIM Congress srl (Ms Dafne Sfoggia) Tel. +39 02 56601.1, Fax +39 02 56609045 - E-mail: recordatiprize2013@aimgroup.eu or visit www.recordati.com/prize.